Halia Therapeutics Pipeline

To serve patients, Halia Therapeutics engages in clinical research with the goal of obtaining regulatory approval of its investigational drugs. Clinical trials allow Halia to evaluate new treatments and learn more about the safety and efficacy information needed to obtain approval of those treatments to then make them available to a broader patient population. More information about Halia clinical trials can be found at clinicaltrials.gov. Halia’s investigational drugs are still at an early stage in development and therefore Halia cannot make expanded access (“compassionate use”) available to its investigational drugs outside of a clinical trial. For more information, please read our full expanded access policy here.

Pipeline

NEK7
INHIBITORS

LRRK2
INHIBITORS

Discovery

IND

Enabling

Phase 1

Phase 2

  • Oral Systemic Multiple Indications 90% 90%
  • Ophthalmology 50% 50%
  • Gastroenterology 50% 50%
  • Neuroinflammation 40% 40%
  • Dermatology 30% 30%
  • Intervertebral Disc Disease 30% 30%
  • Alzheimer's Disease 50% 50%
  • Parkinson's Disease 50% 50%

HT-6184

HT-6184

HT-6258

HT-6283

HT-6515

HT-6153

HT-4253

HT-4403

Next Milestone

PH2 in MDS and
Inflammatory Pain

IND 2024

IND 2024

IND 2024

Pipeline

Halia Therapeutics Pipeline

Halia Therapeutics Policy for Expanded Access to Investigational Drugs

Halia is committed to developing novel meaningful medicines for patients with serious diseases who may benefit from new treatment options. Halia’s current policy for evaluating and responding to requests for individual patient access to investigational drugs intended to treat serious diseases is found below.

Our product pipeline consists of investigational drugs currently being tested in clinical trials and have not yet been approved by the US Food and Drug Administration (FDA). Since the FDA has not approved these investigational drugs, we do not have significant clinical findings demonstrating their safety and effectiveness. Halia’s investigational drugs are currently at a stage in development where we are focused on enrolling patients in our clinical trials and continuing to learn more about our investigational drugs’ safety and efficacy. We encourage patients to speak with their physicians about their eligibility for enrollment in any of Halia’s clinical trials whenever possible. Our clinical trials are designed, conducted, and monitored to advance the development of our investigational drugs to make them more broadly available to patients in the future. Additional information about Halia’s ongoing clinical trials is available at https://clinicaltrials.gov using the search term “Halia.”

Currently, Halia cannot make expanded access available to its investigational drugs.

Halia may revise this expanded access policy at any time in the future, and this posting will be updated should there be any policy change.

For more information regarding our investigational drugs or questions about participation in one of our clinical trials, please submit a request to info@haliatherapeutics.com. Halia personnel will acknowledge receipt of any expanded access questions within ten business days of receipt.

For additional information on expanded access to investigational drugs, visit the FDA’s website.

Contact Us

Corporate Headquarters

3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States

info@haliatx.com |  +1 (385) 355-4315